Aurinia Pharmaceuticals (NASDAQ:AUPH) Given “Overweight” Rating at Cantor Fitzgerald

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP)‘s stock had its “overweight” rating restated by analysts at Cantor Fitzgerald in a report released on Monday, Benzinga reports. They currently have a $10.00 price target on the biotechnology company’s stock. Cantor Fitzgerald’s price target suggests a potential upside of 36.99% from the stock’s current price.

Separately, HC Wainwright restated a “buy” rating and set a $13.00 price objective on shares of Aurinia Pharmaceuticals in a research report on Friday, September 6th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Aurinia Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $10.00.

Aurinia Pharmaceuticals Stock Up 3.8 %

Shares of AUPH traded up $0.27 during mid-day trading on Monday, reaching $7.30. 485,097 shares of the stock traded hands, compared to its average volume of 1,722,479. The stock has a fifty day simple moving average of $6.06 and a 200 day simple moving average of $5.55. Aurinia Pharmaceuticals has a 12-month low of $4.71 and a 12-month high of $10.05. The firm has a market cap of $1.04 billion, a price-to-earnings ratio of -16.98 and a beta of 1.44. The company has a quick ratio of 4.82, a current ratio of 5.33 and a debt-to-equity ratio of 0.18.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last announced its quarterly earnings results on Thursday, August 1st. The biotechnology company reported $0.01 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.01. The company had revenue of $57.10 million during the quarter, compared to the consensus estimate of $54.25 million. Aurinia Pharmaceuticals had a negative net margin of 24.31% and a negative return on equity of 11.84%. The company’s revenue for the quarter was up 37.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.08) earnings per share. Sell-side analysts expect that Aurinia Pharmaceuticals will post 0.13 EPS for the current fiscal year.

Insider Activity

In related news, insider Scott Michael Habig sold 18,249 shares of Aurinia Pharmaceuticals stock in a transaction dated Tuesday, August 6th. The stock was sold at an average price of $5.31, for a total value of $96,902.19. Following the sale, the insider now owns 456,338 shares of the company’s stock, valued at $2,423,154.78. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Corporate insiders own 4.30% of the company’s stock.

Institutional Investors Weigh In On Aurinia Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Armistice Capital LLC increased its holdings in Aurinia Pharmaceuticals by 57.7% in the fourth quarter. Armistice Capital LLC now owns 9,536,000 shares of the biotechnology company’s stock valued at $85,729,000 after purchasing an additional 3,488,000 shares during the period. Goldman Sachs Group Inc. boosted its stake in Aurinia Pharmaceuticals by 39.1% during the fourth quarter. Goldman Sachs Group Inc. now owns 2,048,456 shares of the biotechnology company’s stock worth $18,416,000 after acquiring an additional 576,120 shares in the last quarter. Vanguard Group Inc. increased its position in Aurinia Pharmaceuticals by 1.4% in the 1st quarter. Vanguard Group Inc. now owns 1,531,617 shares of the biotechnology company’s stock valued at $7,673,000 after buying an additional 21,119 shares in the last quarter. Bank of New York Mellon Corp increased its holdings in shares of Aurinia Pharmaceuticals by 18.8% during the second quarter. Bank of New York Mellon Corp now owns 488,721 shares of the biotechnology company’s stock valued at $2,791,000 after acquiring an additional 77,510 shares in the last quarter. Finally, GSA Capital Partners LLP raised its holdings in Aurinia Pharmaceuticals by 196.1% during the first quarter. GSA Capital Partners LLP now owns 349,204 shares of the biotechnology company’s stock worth $1,750,000 after buying an additional 231,260 shares during the last quarter. 36.83% of the stock is currently owned by institutional investors.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.